Bret H Clough1, Eoin P McNeill1, Daniel Palmer1, Ulf Krause2, Thomas J Bartosh1, Christopher D Chaput3, Carl A Gregory4. 1. Institute for Regenerative Medicine, Texas A&M Health Science Center, 206 Olsen Blvd, Room 228 MS1114, College Station, TX 77845, USA. 2. Department of Orthopedic Surgery, Baylor Scott and White Hospital, Texas A&M Health Science Center, 2401 S. 31st St, Temple, TX 76508, USA; Institute for Transfusion Medicine and Transplant Immunology, University Hospital Muenster, 11 Domagkstr, Muenster 48149, Germany. 3. Department of Orthopedic Surgery, Baylor Scott and White Hospital, Texas A&M Health Science Center, 2401 S. 31st St, Temple, TX 76508, USA. 4. Institute for Regenerative Medicine, Texas A&M Health Science Center, 206 Olsen Blvd, Room 228 MS1114, College Station, TX 77845, USA. Electronic address: cgregory@medicine.tamhsc.edu.
Abstract
BACKGROUND CONTEXT: Spine pain and the disability associated with it are epidemic in the United States. According to the National Center for Health Statistics, more than 650,000 spinal fusion surgeries are performed annually in the United States, and yet there is a failure rate of 15%-40% when standard methods employing current commercial bone substitutes are used. Autologous bone graft is the gold standard in terms of fusion success, but the morbidity associated with the procedure and the limitations in the availability of sufficient material have limited its use in the majority of cases. A freely available and immunologically compatible bone mimetic with the properties of live tissue is likely to substantially improve the outcome of spine fusion procedures without the disadvantages of autologous bone graft. PURPOSE: This study aimed to compare a live human bone tissue analog with autologous bone grafting in an immunocompromised rat model of posterolateral fusion. DESIGN/ SETTING: This is an in vitro and in vivo preclinical study of a novel human stem cell-derived construct for efficacy in posterolateral lumbar spine fusion. METHODS: Osteogenically enhanced human mesenchymal stem cells (OEhMSCs) were generated by exposure to conditions that activate the early stages of osteogenesis. Immunologic characteristics of OEhMSCs were evaluated in vitro. The secreted extracellular matrix from OEhMSCs was deposited on a clinical-grade gelatin sponge, resulting in bioconditioned gelatin sponge (BGS). Bioconditioned gelatin sponge was used alone, with live OEhMSCs (BGS+OEhMSCs), or with whole human bone marrow (BGS+hBM). Efficacy for spine fusion was determined by an institutionally approved animal model using 53 nude rats. RESULTS: Bioconditioned gelatin sponge with live OEhMSCs did not cause cytotoxicity when incubated with immunologically mismatched lymphocytes, and OEhMSCs inhibited lymphocyte expansion in mixed lymphocyte assays. Bioconditioned gelatin sponge with live OEhMSC and BGS+hBM constructs induced profound bone growth at fusion sites in vivo, with a comparable rate of fusion with syngeneic bone graft (negative [0 of 10], BGS alone [0 of 10], bone graft [7 of 10], BGS+OEhMSC [10 of 15], and BGS+hBM [8 of 8]). CONCLUSIONS: Collectively, these studies demonstrate that BGS+OEhMSC constructs possess low immunogenicity and drive vertebral fusion with efficiency matching syngeneic bone graft in rodents. We also demonstrate that BGS serves as a promising scaffold for spine fusion when combined with hBM.
BACKGROUND CONTEXT: Spine pain and the disability associated with it are epidemic in the United States. According to the National Center for Health Statistics, more than 650,000 spinal fusion surgeries are performed annually in the United States, and yet there is a failure rate of 15%-40% when standard methods employing current commercial bone substitutes are used. Autologous bone graft is the gold standard in terms of fusion success, but the morbidity associated with the procedure and the limitations in the availability of sufficient material have limited its use in the majority of cases. A freely available and immunologically compatible bone mimetic with the properties of live tissue is likely to substantially improve the outcome of spine fusion procedures without the disadvantages of autologous bone graft. PURPOSE: This study aimed to compare a live human bone tissue analog with autologous bone grafting in an immunocompromised rat model of posterolateral fusion. DESIGN/ SETTING: This is an in vitro and in vivo preclinical study of a novel human stem cell-derived construct for efficacy in posterolateral lumbar spine fusion. METHODS: Osteogenically enhanced human mesenchymal stem cells (OEhMSCs) were generated by exposure to conditions that activate the early stages of osteogenesis. Immunologic characteristics of OEhMSCs were evaluated in vitro. The secreted extracellular matrix from OEhMSCs was deposited on a clinical-grade gelatin sponge, resulting in bioconditioned gelatin sponge (BGS). Bioconditioned gelatin sponge was used alone, with live OEhMSCs (BGS+OEhMSCs), or with whole human bone marrow (BGS+hBM). Efficacy for spine fusion was determined by an institutionally approved animal model using 53 nude rats. RESULTS: Bioconditioned gelatin sponge with live OEhMSCs did not cause cytotoxicity when incubated with immunologically mismatched lymphocytes, and OEhMSCs inhibited lymphocyte expansion in mixed lymphocyte assays. Bioconditioned gelatin sponge with live OEhMSC and BGS+hBM constructs induced profound bone growth at fusion sites in vivo, with a comparable rate of fusion with syngeneic bone graft (negative [0 of 10], BGS alone [0 of 10], bone graft [7 of 10], BGS+OEhMSC [10 of 15], and BGS+hBM [8 of 8]). CONCLUSIONS: Collectively, these studies demonstrate that BGS+OEhMSC constructs possess low immunogenicity and drive vertebral fusion with efficiency matching syngeneic bone graft in rodents. We also demonstrate that BGS serves as a promising scaffold for spine fusion when combined with hBM.
Authors: Anna N A Tosteson; Jon D Lurie; Tor D Tosteson; Jonathan S Skinner; Harry Herkowitz; Todd Albert; Scott D Boden; Keith Bridwell; Michael Longley; Gunnar B Andersson; Emily A Blood; Margaret R Grove; James N Weinstein Journal: Ann Intern Med Date: 2008-12-16 Impact factor: 25.391
Authors: Hyun W Bae; Li Zhao; Linda E A Kanim; Pamela Wong; Deborah Marshall; Rick B Delamarter Journal: J Bone Joint Surg Am Date: 2013-02-20 Impact factor: 5.284
Authors: Candice Sears; Eli Mondragon; Zachary I Richards; Nick Sears; David Chimene; Eoin P McNeill; Carl A Gregory; Akhilesh K Gaharwar; Roland Kaunas Journal: Adv Healthc Mater Date: 2020-03-08 Impact factor: 9.933
Authors: Bret H Clough; Suzanne Zeitouni; Ulf Krause; Christopher D Chaput; Lauren M Cross; Akhilesh K Gaharwar; Carl A Gregory Journal: Stem Cells Transl Med Date: 2018-02-05 Impact factor: 6.940
Authors: Eli Mondragón; Mitzy Cowdin; Francesca Taraballi; Silvia Minardi; Ennio Tasciotti; Carl A Gregory; Roland Kaunas Journal: Front Bioeng Biotechnol Date: 2020-07-03
Authors: Eoin P McNeill; Robert W Reese; Abishek Tondon; Bret H Clough; Simin Pan; Jeremiah Froese; Daniel Palmer; Ulf Krause; David M Loeb; Roland Kaunas; Carl A Gregory Journal: Cell Death Dis Date: 2018-11-26 Impact factor: 8.469
Authors: Robert N Bearden; Shannon S Huggins; Kevin J Cummings; Roger Smith; Carl A Gregory; William B Saunders Journal: Stem Cell Res Ther Date: 2017-10-03 Impact factor: 6.832
Authors: Eoin P McNeill; Suzanne Zeitouni; Simin Pan; Andrew Haskell; Michael Cesarek; Daniel Tahan; Bret H Clough; Ulf Krause; Lauren K Dobson; Mayra Garcia; Christopher Kung; Qingguo Zhao; W Brian Saunders; Fei Liu; Roland Kaunas; Carl A Gregory Journal: Nat Commun Date: 2020-06-15 Impact factor: 14.919